For these reasons, the main goal of the present study has been to identify the smallest BDS-I amino acid sequence able to exert a neuroprotective effect by blocking KV3.4 activity and to provide a new opportunity in the development of potential drugs for AD treatment. The gene discussed is KCNC4; the disease is Alzheimer disease.